Skip to the page

Data / Drug companies / Bortezomib

Bortezomib: 26 companies and 33 products in the FDA NDC directory

Bortezomib is listed in the FDA National Drug Code Directory by 26 companies, with 33 products in commercial distribution. 26 of the products (78.8%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection, powder, lyophilized, for solution; injection, and the newest product started marketing on May 1, 2026.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Companies listing it
26
Products
33
Generic (ANDA) products
26 (78.8%)
Application numbers
19
Routes
Intravenous, Subcutaneous
Brand names
Boruzu, Velcade
openFDA record search
api.fda.gov

Companies that list bortezomib

Ranked by number of products. Finished drugs in commercial distribution.

CompanyProductsMain dosage formsMain marketing categoryNewest product started
BluePoint Laboratories3injection, powder, lyophilized, for solutionGeneric drugs (ANDA)July 31, 2022
Hospira, Inc.3injection, powder, lyophilized, for solutionNew drug applications (NDA)July 27, 2022
Eugia US LLC2injection, powder, lyophilized, for solutionGeneric drugs (ANDA)May 2, 2022
Gland Pharma Limited2injection, powder, lyophilized, for solutionGeneric drugs (ANDA)January 6, 2026
Maia Pharmaceuticals, Inc.2injectionNew drug applications (NDA)August 11, 2022
Amneal Pharmaceuticals LLC1injectionNew drug applications (NDA)September 27, 2024
Apotex Corp.1injection, powder, lyophilized, for solutionGeneric drugs (ANDA)May 2, 2022
Avenacy, LLC1injection, powder, lyophilized, for solutionGeneric drugs (ANDA)May 1, 2026
Camber Pharmaceuticals, Inc.1injection, powder, lyophilized, for solutionGeneric drugs (ANDA)May 3, 2024
Dr. Reddy's Laboratories Inc.1injection, powder, lyophilized, for solutionGeneric drugs (ANDA)July 26, 2022
Fresenius Kabi USA, LLC1injection, powder, lyophilized, for solutionGeneric drugs (ANDA)May 2, 2022
Hikma Pharmaceuticals USA Inc.1injection, powder, lyophilized, for solutionGeneric drugs (ANDA)July 27, 2022
Meitheal Pharmaceuticals Inc.1injection, powder, lyophilized, for solutionGeneric drugs (ANDA)July 26, 2022
Ningbo Shuangcheng Pharmaceutical Co., Ltd1injection, powder, lyophilized, for solutionGeneric drugs (ANDA)December 17, 2025
NorthStar RxLLC1injection, powder, lyophilized, for solutionGeneric drugs (ANDA)November 1, 2024
Novadoz Pharmaceuticals LLC1injection, powder, lyophilized, for solutionGeneric drugs (ANDA)July 26, 2022
Pharmascience Inc.1injection, powder, lyophilized, for solutionGeneric drugs (ANDA)May 2, 2022
Qilu Pharmaceutical Co., Ltd.1injection, powder, lyophilized, for solutionGeneric drugs (ANDA)May 2, 2022
Sagent Pharmaceuticals1injection, powder, lyophilized, for solutionGeneric drugs (ANDA)May 15, 2025
Shilpa Medicare Limited1injectionNew drug applications (NDA)September 25, 2024
Sintetica US LLC1injection, powder, lyophilized, for solutionGeneric drugs (ANDA)July 15, 2023
Somerset Therapeutics, LLC1injection, powder, lyophilized, for solutionGeneric drugs (ANDA)April 29, 2025
Takeda Pharmaceuticals America, Inc.1injection, powder, lyophilized, for solutionNew drug applications (NDA)May 13, 2003
Waverley Pharma Inc1injection, powder, lyophilized, for solutionGeneric drugs (ANDA)June 19, 2018
Zydus Lifesciences Limited1injection, powder, lyophilized, for solutionGeneric drugs (ANDA)May 2, 2022
Zydus Pharmaceuticals USA Inc.1injection, powder, lyophilized, for solutionGeneric drugs (ANDA)May 2, 2022

Dosage forms

Dosage formProductsShare
Injection, powder, lyophilized, for solution2987.9%
Injection412.1%

Marketing categories

Marketing categoryProductsShare
Generic drugs (ANDA)2678.8%
New drug applications (NDA)721.2%

Pharmacologic classes

ClassProducts
Proteasome Inhibitor33

Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.